Regional Health Properties, Inc.
  • Home
  • Company
  • Investor Relations
  • Contact
Select Page

Presentation

KPC-34

Kucera Paper A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms

Kucera Paper Lipid Nucleoside Conjugates for the Treatment of Cancer

Kucers & Pardee Paper Improving Nucleoside Analogs via Lipid Conjugation

Short Summary of KPC34

The Phospholipid Gemcitabine Conjugate, KPC34, is a Novel Treatment for Leukemia

Wake Forest School of Medicine Study Phospholipiddeoxycytidine analogue prodrugs for the treatment of cancer

DHA-dFdC

Short-term Toxicity Study of DHA-dFdC

Study of DHA-dFdC

Synthesis and Cytotoxic Activity of Two Novel 1-Dodecylthio-2-decyloxypropyl-3-phosphatidic Acid Conjugates with Gemcitabine and Cytosine Arabinoside

  • Home
  • Company
  • Investor Relations
  • Contact
© 2025 Regional Health Properties, Inc. All Rights Reserved.
Privacy PolicyTerms of UseSite Map
Disclaimer

You are about to review presentations, reports and/or filings of Regional Health Properties, Inc. (the successor to AdCare Health Systems, Inc.), that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. Regional Health Properties, Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by Regional Health Properties, Inc.

I Accept I Decline